Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications.
Pranav Kumar PrabhakarNavneet KhuranaManish VyasVikas SharmaGaber El-Saber BatihaHarpreet KaurJashanpreet SinghDeepak KumarNeha SharmaAjeet Kumar KaushikRaj KumarPublished in: Pharmaceutics (2023)
Coronavirus, a causative agent of the common cold to a much more complicated disease such as "severe acute respiratory syndrome (SARS-CoV-2), Middle East Respiratory Syndrome (MERS-CoV-2), and Coronavirus Disease 2019 (COVID-19)", is a member of the coronaviridae family and contains a positive-sense single-stranded RNA of 26-32 kilobase pairs. COVID-19 has shown very high mortality and morbidity and imparted a significantly impacted socioeconomic status. There are many variants of SARS-CoV-2 that have originated from the mutation of the genetic material of the original coronavirus. This has raised the demand for efficient treatment/therapy to manage newly emerged SARS-CoV-2 infections successfully. However, different types of vaccines have been developed and administered to patients but need more attention because COVID-19 is not under complete control. In this article, currently developed nanotechnology-based vaccines are explored, such as inactivated virus vaccines, mRNA-based vaccines, DNA-based vaccines, S-protein-based vaccines, virus-vectored vaccines, etc. One of the important aspects of vaccines is their administration inside the host body wherein nanotechnology can play a very crucial role. Currently, more than 26 nanotechnology-based COVID-19 vaccine candidates are in various phases of clinical trials. Nanotechnology is one of the growing fields in drug discovery and drug delivery that can also be used for the tackling of coronavirus. Nanotechnology can be used in various ways to design and develop tools and strategies for detection, diagnosis, and therapeutic and vaccine development to protect against COVID-19. The design of instruments for speedy, precise, and sensitive diagnosis, the fabrication of potent sanitizers, the delivery of extracellular antigenic components or mRNA-based vaccines into human tissues, and the administration of antiretroviral medicines into the organism are nanotechnology-based strategies for COVID-19 management. Herein, we discuss the application of nanotechnology in COVID-19 vaccine development and the challenges and opportunities in this approach.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- drug delivery
- clinical trial
- endothelial cells
- binding protein
- randomized controlled trial
- cardiovascular disease
- stem cells
- hiv infected
- end stage renal disease
- ejection fraction
- dna methylation
- human immunodeficiency virus
- small molecule
- peritoneal dialysis
- men who have sex with men
- induced pluripotent stem cells
- hiv aids